Davita Inc vs Gartner Inc — how do they compare? Davita Inc trades at $179.24 (market cap $11.29B), while Gartner Inc trades at $190.84 (market cap $12.34B). The key difference: Davita Inc and Gartner Inc are close in size by market cap, and Gartner Inc is more actively traded (919,809 versus 582,204). Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Gartner Inc for 64 Days on average.
| DVA | IT | |
|---|---|---|
Market Cap | $11.29B | $12.34B |
Volume | 582,204 | 919,809 |
Sector | Health | Technology |
52-Week High | $240.96 | $258.17 |
52-Week Low | $103.87 | $125.68 |
Typical Hold Time | 113 Days | 64 Days |
Enterprise Value | $24.01B | $14.08B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
Gartner (IT) trades at $195.09, up 5.02% today, showing strong momentum with three consecutive quarterly EPS beats. The stock exhibits bullish technical signals with support at $185 and resistance at $188. Fundamentally, the company maintains robust profitability with 69.63% gross margins and 12% net income margin, though 2025 net income declined to $729M from 2024's $1.3B. Recent news highlights AI advisory demand growth and the upcoming Gartner IT Symposium in October.
Outlook remains positive with analyst consensus at Buy (28%) and $174.63 price target, though current price exceeds target. Key opportunities include strong ROE (113.58%) and AI-driven consulting demand. Risks include negative cash flow trends (-$211M in 2025) and potential fiduciary investigation noted in recent filings. Institutional sentiment appears mixed with 56% Hold ratings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →